Eli Lilly and Co. (LLY.N), a major global pharmaceutical company, has formed a research partnership with Genetic Leap, a startup that uses artificial intelligence (AI) and machine learning for drug discovery. The deal is valued at $409 million and focuses on...
Venture capital giant Flagship Pioneering plans to support the creation and development of about 25 new startups in life sciences or “human health,” sustainability, and artificial intelligence over the next three to five years with a combined $3.6 billion in new...
“Revolutionizing Healthcare Horizons: Delving Deep into Advanced Drug Delivery Systems (ADDS) and Forecasting an Explosive $359.1 Billion Market Growth by 2028, BCC Research Study” Demand for effective solutions has never been so urgent to prevent global...
Biopharma gains a seamless transition from drug discovery through drug product manufacturing SAN DIEGO, June 20, 2024 /PRNewswire/ — Abzena, the leading end-to-end integrated contract and development manufacturing organization (CDMO) for complex biologics and...
Freeline Therapeutics has announced a new name and brand to reflect its focus on developing a new generation of gene therapies and advancing the practice of genetic medicine. Moving forward, the brand will be called Spur Therapeutics. Building on compelling data for...
